Aizhan Abylgazinova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aizhan Abylgazinova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- A.A. Shakirova
NCJSC «Semey Medical University», Semey, Republic of Kazakhstan
1 shared publication - Ainash S. Orazalina
Department of Molecular Biology and Medical Genetics Named After the Academician of National Academy of Sciences Republic of Kazakhstan Raissov T. K., NJSC Semey Medical University, Semey 071400, Kazakhstan
1 shared publication - Aliya Alimbayeva
Department of Pediatrics and Medical Rehabilitation Named after Tusupova D.M., Semey Medical University, Semey 071400, Kazakhstan
1 shared publication - Andrey Yu. Orekhov
Therapy Department, Semey Medical University, Semey 071400, Kazakhstan
1 shared publication - Bakytkul Toktabayeva
Department of Pediatrics named after D.M.Tusupova, NJSC “Semey Medical University”, Semey 071400, Kazakhstan
1 shared publication - G.M. Zhangaliyeva
NCJSC «Semey Medical University», Semey, Republic of Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 28 February 2025
- Published by Semey Medical University in Наука и здравоохранение
- No. 1(27),p. 137-145
THE CONDITION OF THE VASCULAR ENDOTHELIUM IN CHILDREN WITH COVID-19 AND BRONCHO-OBSTRUCTIVE SYNDROME
Introduction: The impact of SARS-CoV-2 infection on the human organism has proven to be more diverse than that of previously known viral infections. However, the full spectrum of the long-term consequences of the disease, especially in children, has not been thoroughly studied. One key area of concern is the development of broncho-obstructive syndrome (BOS) as a post-COVID-19 complication, which involves airway inflammation and hyperreactivity. This study investigates the relationship between endothelial dysfunction and BOS in pediatric patients following SARS-CoV-2 infection. Objective: To explore the endothelial status in children with SARS-CoV-2 infection and its association with the development of BOS, and to assess the role of endothelial dysfunction markers—circulating endothelial cells (CECs), endothelin-1, and nitric oxide metabolites—in this context. Methods: A retrospective study was conducted between 2020 and 2022, involving 486 children. The study included two primary groups: (1) Control: Healthy children with no history of SARS-CoV-2 infection or BOS; children with SARS-CoV-2 infection but no BOS, and (2) Main: Children with BOS but no SARS-CoV-2 infection; children with SARS-CoV-2 infection followed by the development of BOS. Endothelial function was assessed by measuring levels of CECs, endothelin-1, and nitric oxide metabolites. Results: The study found significantly elevated CECs and endothelin-1 levels, along with decreased nitric oxide metabolites, in children who developed BOS following SARS-CoV-2 infection. The highest levels of endothelial dysfunction markers were observed in this group, suggesting a synergistic effect of SARS-CoV-2 infection and BOS on endothelial damage. Notably, 64.3% of children in this group exhibited elevated CEC levels, reflecting severe endothelial dysfunction. Endothelin-1 levels were also significantly higher in children with BOS after SARS-CoV-2 infection (0.46 ± 0.02 fmol/mL) compared to healthy controls and children with BOS without a history of SARS-CoV-2 infection. These findings highlight the critical role of endothelial dysfunction in the pathogenesis of post-COVID-19 respiratory complications. Conclusion: SARS-CoV-2 infection contributes to significant endothelial dysfunction in children, particularly in those who develop BOS. The combination of SARS-CoV-2 infection and BOS exacerbates endothelial damage, which likely plays a critical role in the pathogenesis of post-COVID-19 respiratory complications. These findings suggest the need for further research into therapeutic strategies aimed at correcting endothelial dysfunction, potentially improving outcomes for pediatric patients suffering from long-term respiratory sequelae following COVID-19. Введение: Воздействие инфекции SARS-CoV-2 на человеческий организм оказалось более разнообразным, чем у ранее известных вирусных инфекций. Однако полный спектр долгосрочных последствий заболевания, особенно у детей, еще не был тщательно изучен. Одной из ключевых проблем является развитие бронхообструктивного синдрома (БОС) как постковидного осложнения, которое включает воспаление дыхательных путей и гиперреактивность. Это исследование направлено на изучение связи между эндотелиальной дисфункцией и БОС у детей после инфекции SARS-CoV-2, и на определение роли маркеров эндотелиальной дисфункции - циркулирующих эндотелиальных клеток (ЦЭК), эндотелина-1 и метаболитов оксида азота - в этом контексте. Методы: Ретроспективное исследование было проведено в период с 2020 по 2022 год и охватило 486 детей. Исследование включало две основные группы: (1) Контрольная группа: здоровые дети, не имеющие истории инфекции SARS-CoV-2 или БОС; дети с инфекцией SARS-CoV-2, но без БОС, и (2) Основная группа: дети с БОС, но без инфекции SARS-CoV-2; дети с инфекцией SARS-CoV-2, за которой последовало развитие БОС. Функция эндотелия оценивалась путем измерения уровней ЦЭК, эндотелина-1 и метаболитов оксида азота. Результаты: Исследование показало значительное повышение уровней ЦЭК и эндотелина-1, а также снижение метаболитов оксида азота у детей, развивших БОС после инфекции SARS-CoV-2. Наибольшие уровни маркеров эндотелиальной дисфункции были обнаружены в этой группе, что свидетельствует о синергетическом эффекте инфекции SARS-CoV-2 и БОС на повреждение эндотелия. Особенно важно, что 64,3% детей в этой группе продемонстрировали повышенные уровни ЦЭК, что отражает тяжелую эндотелиальную дисфункцию. Уровни эндотелина-1 также были значительно выше у детей с БОС после инфекции SARS-CoV-2 (0,46 ± 0,02 фмоль/мл) по сравнению...
- 28 February 2025
- Published by Semey Medical University in Наука и здравоохранение
- No. 1(27),p. 137-145
Open AccessTHE CONDITION OF THE VASCULAR ENDOTHELIUM IN CHILDREN WITH COVID-19 AND BRONCHO-OBSTRUCTIVE SYNDROME
Introduction: The impact of SARS-CoV-2 infection on the human organism has proven to be more diverse than that of previously known viral infections. However, the full spectrum of the long-term consequences of the disease, especially in children, has not been thoroughly studied. One key area of concern is the development of broncho-obstructive syndrome (BOS) as a post-COVID-19 complication, which involves airway inflammation and hyperreactivity. This study investigates the relationship between endothelial dysfunction and BOS in pediatric patients following SARS-CoV-2 infection. Objective: To explore the endothelial status in children with SARS-CoV-2 infection and its association with the development of BOS, and to assess the role of endothelial dysfunction markers—circulating endothelial cells (CECs), endothelin-1, and nitric oxide metabolites—in this context. Methods: A retrospective study was conducted between 2020 and 2022, involving 486 children. The study included two primary groups: (1) Control: Healthy children with no history of SARS-CoV-2 infection or BOS; children with SARS-CoV-2 infection but no BOS, and (2) Main: Children with BOS but no SARS-CoV-2 infection; children with SARS-CoV-2 infection followed by the development of BOS. Endothelial function was assessed by measuring levels of CECs, endothelin-1, and nitric oxide metabolites. Results: The study found significantly elevated CECs and endothelin-1 levels, along with decreased nitric oxide metabolites, in children who developed BOS following SARS-CoV-2 infection. The highest levels of endothelial dysfunction markers were observed in this group, suggesting a synergistic effect of SARS-CoV-2 infection and BOS on endothelial damage. Notably, 64.3% of children in this group exhibited elevated CEC levels, reflecting severe endothelial dysfunction. Endothelin-1 levels were also significantly higher in children with BOS after SARS-CoV-2 infection (0.46 ± 0.02 fmol/mL) compared to healthy controls and children with BOS without a history of SARS-CoV-2 infection. These findings highlight the critical role of endothelial dysfunction in the pathogenesis of post-COVID-19 respiratory complications. Conclusion: SARS-CoV-2 infection contributes to significant endothelial dysfunction in children, particularly in those who develop BOS. The combination of SARS-CoV-2 infection and BOS exacerbates endothelial damage, which likely plays a critical role in the pathogenesis of post-COVID-19 respiratory complications. These findings suggest the need for further research into therapeutic strategies aimed at correcting endothelial dysfunction, potentially improving outcomes for pediatric patients suffering from long-term respiratory sequelae following COVID-19. Введение: Воздействие инфекции SARS-CoV-2 на человеческий организм оказалось более разнообразным, чем у ранее известных вирусных инфекций. Однако полный спектр долгосрочных последствий заболевания, особенно у детей, еще не был тщательно изучен. Одной из ключевых проблем является развитие бронхообструктивного синдрома (БОС) как постковидного осложнения, которое включает воспаление дыхательных путей и гиперреактивность. Это исследование направлено на изучение связи между эндотелиальной дисфункцией и БОС у детей после инфекции SARS-CoV-2, и на определение роли маркеров эндотелиальной дисфункции - циркулирующих эндотелиальных клеток (ЦЭК), эндотелина-1 и метаболитов оксида азота - в этом контексте. Методы: Ретроспективное исследование было проведено в период с 2020 по 2022 год и охватило 486 детей. Исследование включало две основные группы: (1) Контрольная группа: здоровые дети, не имеющие истории инфекции SARS-CoV-2 или БОС; дети с инфекцией SARS-CoV-2, но без БОС, и (2) Основная группа: дети с БОС, но без инфекции SARS-CoV-2; дети с инфекцией SARS-CoV-2, за которой последовало развитие БОС. Функция эндотелия оценивалась путем измерения уровней ЦЭК, эндотелина-1 и метаболитов оксида азота. Результаты: Исследование показало значительное повышение уровней ЦЭК и эндотелина-1, а также снижение метаболитов оксида азота у детей, развивших БОС после инфекции SARS-CoV-2. Наибольшие уровни маркеров эндотелиальной дисфункции были обнаружены в этой группе, что свидетельствует о синергетическом эффекте инфекции SARS-CoV-2 и БОС на повреждение эндотелия. Особенно важно, что 64,3% детей в этой группе продемонстрировали повышенные уровни ЦЭК, что отражает тяжелую эндотелиальную дисфункцию. Уровни эндотелина-1 также были значительно выше у детей с БОС после инфекции SARS-CoV-2 (0,46 ± 0,02 фмоль/мл) по сравнению...
- Open Access
Vitamin D Deficiency and Maternal Diseases as Risk Factors for the Development of Macrosomia in Newborns
Background: The aim is to assess the association between the level of vitamin D, maternal diseases, and macrosomia in newborns. Methods: This study included 258 full-term newborns (86 newborns with macrosomia; and 172 newborns with normal weight). Enzyme immunoassays for the determination of vitamin D were performed. Results: Newborns with macrosomia were statistically significantly more likely to have severe vitamin D deficiency compared with control (13.5 ± 6.7 ng/mL vs. 21.3 ± 12.1 ng/mL; p < 0.05). In the main group, severe deficiency was found in 40.7% of newborns, in the control group this rate was 5.8% (χ2 = 71,788, df = 3, p < 0.001). Multiple regression analysis shows that statistically significant risk factors for the development of macrosomia were vitamin D deficiency in the cord blood (OR = 2.29), maternal age over 36 years old (OR = 19.54), and hypothyroidism (OR = 9.35). Conclusion: the results of our study demonstrate relationship between macrosomia in newborns and vitamin D deficiency in the cord blood, maternal overweight and obesity, maternal age and thyroid disease.
Open AccessVitamin D Deficiency and Maternal Diseases as Risk Factors for the Development of Macrosomia in Newborns
Background: The aim is to assess the association between the level of vitamin D, maternal diseases, and macrosomia in newborns. Methods: This study included 258 full-term newborns (86 newborns with macrosomia; and 172 newborns with normal weight). Enzyme immunoassays for the determination of vitamin D were performed. Results: Newborns with macrosomia were statistically significantly more likely to have severe vitamin D deficiency compared with control (13.5 ± 6.7 ng/mL vs. 21.3 ± 12.1 ng/mL; p < 0.05). In the main group, severe deficiency was found in 40.7% of newborns, in the control group this rate was 5.8% (χ2 = 71,788, df = 3, p < 0.001). Multiple regression analysis shows that statistically significant risk factors for the development of macrosomia were vitamin D deficiency in the cord blood (OR = 2.29), maternal age over 36 years old (OR = 19.54), and hypothyroidism (OR = 9.35). Conclusion: the results of our study demonstrate relationship between macrosomia in newborns and vitamin D deficiency in the cord blood, maternal overweight and obesity, maternal age and thyroid disease.